WO2001013900A3 - Compositions for the treatment of cardiovascular diseases containing pyridoxal compounds and cardiovascular compounds - Google Patents

Compositions for the treatment of cardiovascular diseases containing pyridoxal compounds and cardiovascular compounds Download PDF

Info

Publication number
WO2001013900A3
WO2001013900A3 PCT/CA2000/001020 CA0001020W WO0113900A3 WO 2001013900 A3 WO2001013900 A3 WO 2001013900A3 CA 0001020 W CA0001020 W CA 0001020W WO 0113900 A3 WO0113900 A3 WO 0113900A3
Authority
WO
WIPO (PCT)
Prior art keywords
compounds
cardiovascular
pyridoxal
compositions
treatment
Prior art date
Application number
PCT/CA2000/001020
Other languages
French (fr)
Other versions
WO2001013900A2 (en
Inventor
Rajat Sethi
Wasimul Haque
Original Assignee
Medicure Int Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medicure Int Inc filed Critical Medicure Int Inc
Priority to CA002383252A priority Critical patent/CA2383252A1/en
Priority to EP00956009A priority patent/EP1210117A2/en
Priority to AU68144/00A priority patent/AU783855B2/en
Priority to JP2001518038A priority patent/JP2003507418A/en
Publication of WO2001013900A2 publication Critical patent/WO2001013900A2/en
Publication of WO2001013900A3 publication Critical patent/WO2001013900A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4415—Pyridoxine, i.e. Vitamin B6
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Abstract

Methods for treating cardiovascular and related diseases such as hypertrophy, hypertension, congestive heart failure, ischemia, ischemia reperfusion injuries in various organs, arrhythmia, and myocardial infarction, are described. The methods are directed to concurrently administering a compound such as pyridoxal-5'-phosphate, pyridoxamine, pyridoxal, or a 3-acylated pyridoxal analogue with a therapeutic cardiovascular compound.
PCT/CA2000/001020 1999-08-24 2000-08-24 Compositions for the treatment of cardiovascular diseases containing pyridoxal compounds and cardiovascular compounds WO2001013900A2 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
CA002383252A CA2383252A1 (en) 1999-08-24 2000-08-24 Treatment of cardiovascular related pathologies
EP00956009A EP1210117A2 (en) 1999-08-24 2000-08-24 Compositons for the treatment of cardiovascular diseases containing pyridoxal compounds and cardiovascular compounds
AU68144/00A AU783855B2 (en) 1999-08-24 2000-08-24 Compositions for the treatment of cardiovascular diseases containing pyridoxal compounds and cardiovascular compounds
JP2001518038A JP2003507418A (en) 1999-08-24 2000-08-24 Treatment of cardiovascular disease and related diseases

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US15041599P 1999-08-24 1999-08-24
US60/150,415 1999-08-24

Publications (2)

Publication Number Publication Date
WO2001013900A2 WO2001013900A2 (en) 2001-03-01
WO2001013900A3 true WO2001013900A3 (en) 2002-02-07

Family

ID=22534418

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CA2000/001020 WO2001013900A2 (en) 1999-08-24 2000-08-24 Compositions for the treatment of cardiovascular diseases containing pyridoxal compounds and cardiovascular compounds

Country Status (6)

Country Link
US (7) US6677356B1 (en)
EP (2) EP1210117A2 (en)
JP (1) JP2003507418A (en)
AU (1) AU783855B2 (en)
CA (1) CA2383252A1 (en)
WO (1) WO2001013900A2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8067444B2 (en) 2003-06-20 2011-11-29 Nephrogenex, Inc. Pyridoxamine for the treatment of diabetic intermediaries and post-amadori inhibition

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR0008857A (en) * 1999-03-08 2001-12-18 Medicure Inc Pyridoxal analogues for vitaminab-6 disorders
WO2001003682A2 (en) * 1999-07-13 2001-01-18 Medicure Inc. Use of pyridoxin derivatives for the treatment of diabetes and related complications
US7442689B2 (en) 2000-02-29 2008-10-28 Medicure International Inc. Cardioprotective phosphonates and malonates
EP1278526A2 (en) * 2000-03-28 2003-01-29 Medicure International Inc. Treatment of cerebrovascular disease
US6897228B2 (en) * 2000-07-07 2005-05-24 Medicure International Inc. Pyridoxine and pyridoxal analogues: new uses
US20040121988A1 (en) * 2001-03-28 2004-06-24 Medicure International Inc. Treatment of cerebrovascular disease
NO20024880L (en) * 2002-03-19 2003-09-22 Per Hamre Composition containing phosphate
US20040186077A1 (en) * 2003-03-17 2004-09-23 Medicure International Inc. Novel heteroaryl phosphonates as cardioprotective agents
AU2004224566A1 (en) * 2003-03-27 2004-10-07 Medicure Inc. Compositions for treating angina
EP1610783A2 (en) * 2003-03-27 2006-01-04 Medicure Inc. Modulation of cell death
US7169805B2 (en) * 2003-05-28 2007-01-30 Nicox S.A. Captopril derivatives
WO2005089639A2 (en) * 2004-03-16 2005-09-29 Talarico M D Matthew T Method for vascular dysregulation
EP1750862B1 (en) * 2004-06-04 2011-01-05 Teva Pharmaceutical Industries Ltd. Pharmaceutical composition containing irbesartan
CA2570048A1 (en) * 2004-07-07 2006-01-12 Medicure International Inc. Combination therapies employing platelet aggregation drugs
US20080032952A1 (en) * 2004-07-09 2008-02-07 Marjorie Zettler Combination Therapies Employing Nicotinic Acid Derivatives or Fibric Acid Derivatives
US20070060549A1 (en) * 2004-08-10 2007-03-15 Friesen Albert D Combination therapies employing ace inhibitors and uses thereof for the treatment of diabetic disorders
CA2575849A1 (en) * 2004-08-10 2006-02-16 Medicure International Inc. Combination therapies employing vitamin b6 related compounds and ace inhibitors and uses thereof for the treatment of diabetic disorders
US20080004320A1 (en) * 2004-09-06 2008-01-03 Kowa Co., Ltd. Remedy for Glomerular Disease
EP1796685A1 (en) * 2004-09-24 2007-06-20 Medicure International Inc. Pyridoxal-5´-phosphate and related compounds in combination with therapeutic cadiovascular compounds for treating angina.
WO2006056038A1 (en) * 2004-09-24 2006-06-01 Medicure International Inc. Pyridoxal-5-phosphate and stent for the treatment and prevention of atherosclerosis and restenosis
US20060094749A1 (en) * 2004-10-28 2006-05-04 Medicure International Inc. Substituted pyridoxines as anti-platelet agents
AU2005304220A1 (en) * 2004-10-28 2006-05-18 Medicure International Inc. Dual antiplatelet/anticoagulant pyridoxine analogs
US7459468B2 (en) * 2004-10-28 2008-12-02 Medicure International, Inc. Aryl sulfonic pyridoxines as antiplatelet agents
CA2528191A1 (en) * 2004-11-26 2006-05-26 Medicure International Inc. Novel formulation of pyridoxal 5'-phosphate and method of preparation
WO2006056079A1 (en) * 2004-11-26 2006-06-01 Medicure International Inc. Formulations of pyridoxal -5'-phosphate and methods of preparation
US20060128797A1 (en) * 2004-12-15 2006-06-15 Yanming Wang Method and composition for resuscitation
WO2006072172A1 (en) * 2005-01-05 2006-07-13 Medicure International Inc. Compounds and methods for regulating triglyceride levels
CA2503087A1 (en) * 2005-03-30 2006-09-30 Medicure International Inc. Intravenous formulations of pyridoxal 5'-phosphate and method of preparation
SE529780C2 (en) * 2005-08-04 2007-11-20 Hexagon Metrology Ab Measuring method and measuring device for use in measuring systems such as coordinate measuring machines
US8158146B2 (en) 2005-09-28 2012-04-17 Teva Pharmaceutical Industries Ltd. Stable combinations of amlodipine besylate and benazepril hydrochloride
EP1790331A1 (en) * 2005-11-28 2007-05-30 Medicure International Inc. Use of pyridoxal-5-phosphate for the treatment of cardiovascular and related pathologies
WO2007059631A1 (en) * 2005-11-28 2007-05-31 Medicure International Inc. Selected dosage for the treatment of cardiovascular and related pathologies
EP3255432B1 (en) 2006-04-24 2019-01-23 Critical Care Diagnostics, Inc. Predicting mortality and detecting severe disease
WO2007121588A1 (en) * 2006-04-25 2007-11-01 Medicure International Inc. Treatment of atrial fibrillation
PT2049127E (en) * 2006-05-23 2014-12-23 Univ Connecticut N-methanocarba derivatives to treat cardiac diseases
WO2009125944A2 (en) * 2008-04-10 2009-10-15 한올제약주식회사 Pharmaceutical preparation containing non-dihydropyridine calcium channel blocker and angiotensin-2 receptor blocker
WO2009129454A2 (en) 2008-04-18 2009-10-22 Critical Care Diagnostics, Inc. Predicting risk of major adverse cardiac events
CA2749903C (en) * 2009-01-23 2016-09-06 Jae Hyun Park Solid pharmaceutical composition comprising amlodipine and losartan and process for producing same
ES2654363T3 (en) 2010-02-22 2018-02-13 University Of Connecticut AMP derivatives to treat heart disease
US20160310524A1 (en) * 2013-12-13 2016-10-27 Ralph Ankenman Compositions and methods for treating dysregulated systems
WO2016046674A1 (en) * 2014-09-28 2016-03-31 Mohan M Alapati Compositions and methods for the treatment of moderate to severe pain
WO2018002673A1 (en) 2016-07-01 2018-01-04 N4 Pharma Uk Limited Novel formulations of angiotensin ii receptor antagonists
CN107418989A (en) * 2017-08-21 2017-12-01 浙江工业大学 A kind of method of lipase-catalyzed online synthesis N (5 sucrose ester valeryl) metoprolol
CN108508218A (en) * 2018-07-09 2018-09-07 复旦大学附属中山医院 Early diagnosis markers and its application of the advanced glycation end products CML as myocardial ischemia-reperfusion injury

Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3282778A (en) * 1960-09-02 1966-11-01 Lohel Mervyn Joseph Medicinal preparation containing acetyl salicylic acid and a pyridoxine compound
DE2845484A1 (en) * 1978-10-19 1980-04-30 Groening Ruediger Inhibiting gastrointestinal degradation of medicaments - by co:administration of additives undergoing sacrificial degradation
EP0270026A2 (en) * 1986-11-29 1988-06-08 Vesta Medicines (Proprietary) Limited Pharmaceutical preparation comprising vitamin B6
FR2641189A1 (en) * 1988-06-20 1990-07-06 Timol Mamoojee Pharmaceutical compositions containing acetylsalicylic acid and vitamin B6
US5254572A (en) * 1987-11-27 1993-10-19 Vesta Medicines (Pty) Ltd. Method and composition for supplementing vitamin B6 where the PN-PLP pathway is disturbed
US5288498A (en) * 1985-05-01 1994-02-22 University Of Utah Research Foundation Compositions of oral nondissolvable matrixes for transmucosal administration of medicaments
CA2123935A1 (en) * 1993-06-04 1994-12-05 Jeffry W. Kreamer Aspirin and vitamin and/or trace element compositions for the amelioration and treatment of vascular disease
WO1998019690A1 (en) * 1996-11-06 1998-05-14 Bristol-Myers Squibb Company Method for treating alzheimer's disease
WO2000053606A1 (en) * 1999-03-08 2000-09-14 Medicure Inc. Pyridoxal analogues for vitamin b-6 disorders

Family Cites Families (112)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3206463A (en) 1965-09-14 Pyridoxine aspartate and its process of preparation
FR846376A (en) 1938-08-23 1939-09-15 Air navigation and aerial bombardment equipment
DE863754C (en) 1951-04-17 1953-01-19 Gottfried Korbmacher Floor brake with brake shoes that can be inserted between the wheel and the roadway on motor vehicles
US2904551A (en) * 1956-11-14 1959-09-15 Merck & Co Inc Chemical compounds and processes of preparing the same
GB966805A (en) 1961-05-15 1964-08-19 Merck & Co Inc Process for the preparation of 2-methyl-3-hydroxypyridines
NL120995C (en) 1962-07-05
FR5552M (en) 1966-04-28 1967-11-20
FR5801M (en) 1966-06-27 1968-02-19
GB1228142A (en) 1967-03-31 1971-04-15
FR6453M (en) 1967-06-13 1968-11-12
DE1767499A1 (en) 1968-05-16 1971-09-09 Merck Patent Gmbh Process for the production of durable vitamin preparations
ES360566A1 (en) 1968-11-22 1970-10-16 Made Labor Sa Pyridoxine alpha-ketoglutarate and derivatives thereof
GB1236531A (en) 1969-02-12 1971-06-23 Soc D Etudes Prod Chimique Adenin derivative
JPS4821959B1 (en) 1969-03-31 1973-07-02
US3910921A (en) 1970-01-08 1975-10-07 Soc D Etudes Prod Chimique Papaverine monopyridoxal phosphate
GB1297080A (en) 1970-04-17 1972-11-22
FR2101010A1 (en) 1970-08-06 1972-03-31 Lyocentre Sparteine mono-and dipyridoxinates and prepn - as tonics for cardiova disorders
GB1493993A (en) 1975-05-16 1977-12-07 Howard A Dietary supplement and dietary methods employing said supplement for the treatment of obesity
US4036844A (en) 1972-04-04 1977-07-19 Beecham Group Limited Aryloxypyridines
US4053607A (en) 1972-04-04 1977-10-11 Beecham Group Limited Aryloxypyridine for treating hyperglycaemia
GB1360536A (en) 1972-04-25 1974-07-17 Soc D Etudes Prod Chimique Pyridoxyl-l-aspartic acid salt
BE790118A (en) 1972-10-09 1973-02-01 Made Labor Sa PYRIDOXAL AND PYRIDOXAMINE ALPHA-CETOGLUTARATE DERIVATIVES,
US4032534A (en) 1973-03-22 1977-06-28 Ferlus-Chimie S.A. Certain 2-(2-thioethyl)thiazolidine-4-carboxylic acids
FR2255883A1 (en) 1973-12-28 1975-07-25 Centre Etd Ind Pharma Clofibric acid-vitamin B6 compsns. - with synergistic hypocholesterolaemic and normolipaemic activity
FR2275209A1 (en) 1974-06-21 1976-01-16 Synthelabo Oxoalkyl esters of vincamine acids - and their pharm. acceptable salts for use in medicine
FR2276048A1 (en) 1974-06-27 1976-01-23 Synthelabo NEW CYCLOHEXANOL ESTERS, THEIR SALTS, THEIR PREPARATION AND THE MEDICINAL PRODUCTS CONTAINING THEM
DE2461742C2 (en) 1974-12-28 1983-01-27 Steigerwald Arzneimittelwerk Gmbh, 6100 Darmstadt Pyridoxine-5'-phosphoric acid ester derivatives and their preparation and pharmaceuticals containing these compounds
GB1525885A (en) 1976-05-11 1978-09-20 Soc D Etudes Prod Chimique Vincamine salt of pyridoxal phosphate
JPS5417130A (en) 1977-07-08 1979-02-08 Chugai Pharmaceut Co Ltd Remedy for cardio-vasocular diseases
BE863754A (en) 1978-02-08 1978-05-29 Dechamps Pierre NEW VINCAMINE DERIVATIVES FOR USE AS BRAIN CIRCULATION REGULATORS
FR2428640A1 (en) 1978-06-12 1980-01-11 Parcor 5-Piperazino:alkoxy:methyl-pyridine cpds. - with antiinflammatory, diuretic and vaso-protective properties
US4167562A (en) 1978-08-28 1979-09-11 Evers H Ray Method and composition for treating arteriosclerosis
GB2075983B (en) * 1980-05-19 1984-05-10 Labaz Nv Pyridoxine derivatives process for preparing them and use in therapeutics
IL62602A (en) 1980-05-19 1984-06-29 Labaz Sanofi Nv Pyridoxine derivatives,their preparation and pharmaceutical compositions containing them
US4753956A (en) * 1981-01-02 1988-06-28 Pfizer Inc. Hypoglycemic 5-substituted oxazolidine-2,4-diones
IT1141070B (en) 1980-09-22 1986-10-01 Luso Farmaco Inst USE OF ALPHA-KETOGLUTARATE OF PYRIDOXY IN THE PROPHYLAXIS OF HYPERLACTACIDEMIA
US4369172A (en) 1981-12-18 1983-01-18 Forest Laboratories Inc. Prolonged release therapeutic compositions based on hydroxypropylmethylcellulose
US4528197A (en) 1983-01-26 1985-07-09 Kabivitrum Ab Controlled triglyceride nutrition for hypercatabolic mammals
IN160104B (en) 1983-04-05 1987-06-27 Scras
US4735950A (en) 1983-04-05 1988-04-05 Societe De Conseils De Recherches Et D'applications Scientifiques (S.C.R.A.S) Furo-(3,4-C)-pyridine derivatives and therapeutic composition containing the same
US4515771A (en) 1983-04-11 1985-05-07 Fine Daniel H Composition and method for the preventative treatment of dental disease and apparatus for dispensing said composition
GB8330517D0 (en) 1983-11-16 1983-12-21 Scras 6-vinyl-furo-(3,4-c)pyridine derivatives
GB8330658D0 (en) 1983-11-17 1983-12-29 Scras 7-carboxymethoxy-furo-(3,4-c)-pyridine derivatives
IT1212792B (en) 1983-11-30 1989-11-30 Egidio Aldo Moja DIETARY SUPPLEMENT AND PRE-PACKED FOOD THAT CONTAINS IT PREPARATION PROCEDURE AND METHOD OF ADMINISTRATION
US5272165A (en) 1984-03-19 1993-12-21 The Rockefeller University 2-alkylidene-aminoguanidines and methods of use therefor
US5130324A (en) 1984-03-19 1992-07-14 The Rockefeller University 2-alkylidene-aminoguanidines and methods of use therefor
US4567179A (en) 1984-10-11 1986-01-28 Pfizer, Inc. Antiinflammatory salts of piroxicam
DE3519693A1 (en) 1985-06-01 1987-01-02 Basf Ag PYRIDINE DERIVATIVES, THEIR PRODUCTION AND USE
US4837239A (en) 1985-08-23 1989-06-06 Syntex (U.S.A.) Inc. Cardiotonic phosphodiesterase inhibitors complexed with water soluble vitamins
US5053396A (en) 1985-08-27 1991-10-01 Blass David H Therapeutic composition
US4735956A (en) 1985-09-13 1988-04-05 Merck & Co., Inc. Certain 1,4-dihydro-2,6-di-lower hydrocarbyl-4-heterocyclic-3,5-pyridine dicarboxylates which are useful as calcium channel blockers
US4605741A (en) 1985-11-13 1986-08-12 Lisapharma Spa Pharmaceutically active salt derivative of 3-hydroxy-5-(hydroxymethyl)-2-methylisonicotinaldehyde phosphate
DE3634016A1 (en) 1986-04-17 1987-10-29 Lohmann Gmbh & Co Kg AREA-BASED THERAPEUTIC SYSTEM, METHOD FOR THE PRODUCTION THEREOF AND ITS USE
US5210083A (en) 1986-07-17 1993-05-11 Ed. Geistlich Sohne A.G. Fur Chemische Industrie Pharmaceutical compositions
US5563126A (en) 1986-11-20 1996-10-08 Metabolite Laboratories Method for treatment and prevention of deficiencies of vitamins B12, folic acid, and B6
US5631271A (en) 1986-11-29 1997-05-20 Serfontein; Willem J. Methods and preparations for the treatment and prophylaxis of metabolic disturbances
US4843071A (en) 1986-12-05 1989-06-27 Serotonin Industries Of Charleston Method and composition for treating obesity, drug abuse, and narcolepsy
US5385938B1 (en) * 1986-12-23 1997-07-15 Tristrata Inc Method of using glycolic acid for treating wrinkles
US5288716A (en) 1987-02-18 1994-02-22 Ulrich Speck Use of pyridoxine derivatives in the prevention and treatment of hyperlipidaemia and atherosclerosis
DE3705549A1 (en) 1987-02-18 1988-09-01 Ulrich Speck USE OF PYRIDOXINE DERIVATIVES IN THE PROPHYLAXIS AND THERAPY OF HYPERLIPIDAEMIA AND ATHEROSCLEROSIS
SE8701662L (en) 1987-04-22 1988-10-23 Gelder Nico M Van SETTING AND AGENTS FOR TREATING NEUROLOGICAL DISEASES, EXAMPLE, MIGRAEN THROUGH THE OPERATION OF NERV CELLS
US5213813A (en) 1987-05-29 1993-05-25 The University Of Vermont Pyridoxal-5'-phosphate as an in vitro blood platelet stabilizer
ES2043897T3 (en) 1988-01-28 1994-01-01 Koeltringer Peter COMBINATION PREPARATION, ESPECIALLY FOR THE TREATMENT OF NERVOUS CELL DISEASES.
NZ228285A (en) 1988-03-11 1991-08-27 Teikoku Seiyaku Kk Pharmaceutical composition comprising a polypeptide and adapted for intravaginal administration
US5254557A (en) 1988-05-09 1993-10-19 Beecham Group P.L.C. Compound and treatment
US5088977A (en) 1988-12-21 1992-02-18 Drug Delivery Systems Inc. Electrical transdermal drug applicator with counteractor and method of drug delivery
US5001115A (en) 1989-05-17 1991-03-19 University Of Florida Prodrugs of biologically active hydroxyaromatic compounds
GB8918368D0 (en) 1989-08-11 1989-09-20 Amco Chemie Gmbh Compositions for treating obstructive airways disease
US5527527A (en) * 1989-09-07 1996-06-18 Alkermes, Inc. Transferrin receptor specific antibody-neuropharmaceutical agent conjugates
DE4016963A1 (en) 1990-05-25 1991-11-28 Steigerwald Arzneimittelwerk USE OF MAGNESIUM PYRIDOXAL 5'-PHOSPHATE GLUTAMINATE TO PREVENT ILLNESSES ARISING AS A RESULT OF DISSOLUTION
US5668117A (en) * 1991-02-22 1997-09-16 Shapiro; Howard K. Methods of treating neurological diseases and etiologically related symptomology using carbonyl trapping agents in combination with previously known medicaments
US5385937A (en) 1991-04-10 1995-01-31 Brigham & Women's Hospital Nitrosation of homocysteine as a method for treating homocysteinemia
GB2254556B (en) 1991-04-11 1995-04-12 Fisons Plc Formulations containing linolenic acid
CA2103050A1 (en) 1991-05-15 1992-11-16 Yung-Chi Cheng Determination of prodrugs metabolizable by the liver and therapeutic use thereof
FR2678622B1 (en) 1991-07-03 1994-11-18 Adir NEW VANADIUM COMPLEXES, THEIR PREPARATION PROCESS AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING THEM.
JPH07503010A (en) 1992-01-06 1995-03-30 ヘルス・メインテナンス・プログラムズ，インコーポレイテッド Pharmaceutically active antioxidant-containing composition and method for preventing and treating restenosis after angioplasty using the composition
EP0555681A1 (en) * 1992-02-13 1993-08-18 E.R. SQUIBB & SONS, INC. Use of a combination of potassium channel activators and sulfhydryl containing compounds for the manufacture of a medicament for the treatment of ischemia and myocarolial infarct
WO1993025219A1 (en) 1992-06-12 1993-12-23 Cephalon, Inc. Prevention and treatment of peripheral neuropathy
US5420112A (en) 1992-06-12 1995-05-30 Lewis; Michael E. Prevention and treatment of peripheral neuropathy
US5330743A (en) 1992-11-12 1994-07-19 Magnetic Research, Inc. Aminosaccharide contrast agents for magnetic resonance images
JPH06172220A (en) * 1992-12-03 1994-06-21 Upjohn Co:The Medicinal composition for therapy of ischemic disease
US5795873A (en) 1992-12-29 1998-08-18 Metabolite Laboratories, Inc. Method for treatment and prevention of deficiencies of vitamins B12, folic acid and B6
TW268948B (en) 1993-04-02 1996-01-21 Senju Pharma Co
US5443643A (en) * 1993-04-21 1995-08-22 Axis Usa, Inc. Heatless resin coating system
JPH0817174B2 (en) * 1993-11-10 1996-02-21 キヤノン販売株式会社 Method of modifying insulating film
DE4344751A1 (en) 1993-12-28 1995-06-29 Carl Heinrich Dr Weischer New vitamin=B6 ester cpds. of sulphur-contg. carboxylic acids
US5504090A (en) 1994-03-30 1996-04-02 Trustees Of The University Of Pennsylvania Compositions and methods for the prevention and treatment of ischemia-reperfusion organ injury
JP2757775B2 (en) 1994-05-23 1998-05-25 日本電気株式会社 System clock matching system and telephone switching network with system clock matching function
DE4440875A1 (en) * 1994-11-16 1996-06-05 Santrade Ltd Device for the production of pastilles
ATE300308T1 (en) 1994-12-12 2005-08-15 Omeros Corp IRGINATION SOLUTION AND THE USE THEREOF FOR THE PERIOPERATIVE INHIBITION OF PAIN, INFLAMMATION AND SPASMS IN A WOUND
US5569459A (en) 1995-02-15 1996-10-29 Bio-Virus Research Incorporated Pharmaceutical compositions for the management of premenstrual syndrome and alleviation of menopausal disorders
US5733916A (en) 1995-03-24 1998-03-31 The Trustees Of The University Of Pennsylvania Prevention and treatment of ischemia-reperfusion and endotoxin-related injury using adenosine and purino receptor antagonists
US5610115A (en) * 1995-07-20 1997-03-11 Samsung General Chemicals Co., Ltd. Organic carrier supported metallocene catalyst for olefin polymerization
US5874443A (en) 1995-10-19 1999-02-23 Trega Biosciences, Inc. Isoquinoline derivatives and isoquinoline combinatorial libraries
US5833998A (en) 1995-11-06 1998-11-10 The Procter & Gamble Company Topical compositions for regulating the oily/shiny appearance of skin
US5733884A (en) 1995-11-07 1998-03-31 Nestec Ltd. Enteral formulation designed for optimized wound healing
US5663726A (en) * 1995-12-01 1997-09-02 U.S. Philips Corporation High speed variable-length decoder arrangement with reduced memory requirements for tag stream buffering
US5874420A (en) 1995-12-26 1999-02-23 Allegheny University Of The Health Sciences Process for regulating vagal tone
US5847008A (en) 1996-02-02 1998-12-08 Merck & Co., Inc. Method of treating diabetes and related disease states
US5859051A (en) 1996-02-02 1999-01-12 Merck & Co., Inc. Antidiabetic agents
US5834446A (en) 1996-06-21 1998-11-10 Queen's University At Kingston Nerve process growth modulators
GB9613470D0 (en) * 1996-06-27 1996-08-28 Ciba Geigy Ag Small solid oral dosage form
US5770215A (en) 1997-01-06 1998-06-23 Moshyedi; Emil Payman Multivitamin/vascular occlusion inhibiting composition
US5804594A (en) 1997-01-22 1998-09-08 Murad; Howard Pharmaceutical compositions and methods for improving wrinkles and other skin conditions
US5888514A (en) 1997-05-23 1999-03-30 Weisman; Bernard Natural composition for treating bone or joint inflammation
EP0891719A1 (en) 1997-07-14 1999-01-20 N.V. Nutricia Nutritional composition containing methionine
US6610480B1 (en) 1997-11-10 2003-08-26 Genentech, Inc. Treatment and diagnosis of cardiac hypertrophy
US6051587A (en) * 1998-04-16 2000-04-18 Medicure, Inc. Treatment of iatrogenic and age-related hypertension and pharmaceutical compositions useful therein
US6043259A (en) * 1998-07-09 2000-03-28 Medicure Inc. Treatment of cardiovascular and related pathologies
US5904090A (en) * 1998-10-01 1999-05-18 Dart Industries Inc. Basket and drive arrangement for salad spinner
EP1268498B1 (en) 2000-02-29 2005-04-13 Medicure International Inc. Cardioprotective phosphonates
AU2001272263B2 (en) * 2000-07-07 2005-12-15 Medicure International Inc. Pyridoxine and pyridoxal analogues: cardiovascular therapeutics

Patent Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3282778A (en) * 1960-09-02 1966-11-01 Lohel Mervyn Joseph Medicinal preparation containing acetyl salicylic acid and a pyridoxine compound
DE2845484A1 (en) * 1978-10-19 1980-04-30 Groening Ruediger Inhibiting gastrointestinal degradation of medicaments - by co:administration of additives undergoing sacrificial degradation
US5288498A (en) * 1985-05-01 1994-02-22 University Of Utah Research Foundation Compositions of oral nondissolvable matrixes for transmucosal administration of medicaments
EP0270026A2 (en) * 1986-11-29 1988-06-08 Vesta Medicines (Proprietary) Limited Pharmaceutical preparation comprising vitamin B6
US5254572A (en) * 1987-11-27 1993-10-19 Vesta Medicines (Pty) Ltd. Method and composition for supplementing vitamin B6 where the PN-PLP pathway is disturbed
FR2641189A1 (en) * 1988-06-20 1990-07-06 Timol Mamoojee Pharmaceutical compositions containing acetylsalicylic acid and vitamin B6
CA2123935A1 (en) * 1993-06-04 1994-12-05 Jeffry W. Kreamer Aspirin and vitamin and/or trace element compositions for the amelioration and treatment of vascular disease
WO1998019690A1 (en) * 1996-11-06 1998-05-14 Bristol-Myers Squibb Company Method for treating alzheimer's disease
WO2000053606A1 (en) * 1999-03-08 2000-09-14 Medicure Inc. Pyridoxal analogues for vitamin b-6 disorders

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
AYBAK M ET AL: "EFFECT OF ORAL PYRIDOXINE HYDROCHLORIDE SUPPLEMENTATION ON ARTERIALBLOOD PRESSURE IN PATIENTS WITH ESSENTIAL HYPERTENSION", ARZNEIMITTEL FORSCHUNG. DRUG RESEARCH,EDITIO CANTOR. AULENDORF,DE, vol. 45, no. 112, 1995, pages 1271 - 1273, XP000961002, ISSN: 0004-4172 *
FOLSOM A R ET AL: "PROSPECTIVE STUDY OF CORONARY HEART DISEASE INCIDENCE IN RELATION TO FASTING TOTAL HOMOCYSTEINE, RELATED GENETIC POLYMORPHISMS, AND B VITAMINS THE ATHEROSCLEROSIS RISK IN COMMUNITIES (ARIC) STUDY", CIRCULATION,AMERICAN HEART ASSOCIATION, DALLAS, TX,US, vol. 98, no. 3, 21 July 1998 (1998-07-21), pages 204 - 210, XP000965312, ISSN: 0009-7322 *
KUBYSHKIN V F ET AL: "Comparative characteristics of the arrhythmic syndrome and the possibility for its coenzyme correction in dilated and hypertrophic cardiomyopathy. S ravnitel'naia kharakteristika aritmicheskogo sindroma i vozmozhnosti ego kofermentnoi korrektsii pri dilatatsionnoi i gipertroficheskoi kardiomiopatii", TERAPEVTICHESKII ARKHIV - THERAPEUTIC ARCHIVES,MOSCOW,RU, vol. 61, no. 9, 1989, pages 82 - 85, XP000965693, ISSN: 0040-3660 *
LEVY H A ET AL: "PYRIDOXINE DEFICIENCY IN CONGESTIVE HEART FAILURE (25037)", PROCEEDINGS OF THE SOCIETY FOR EXPERIMENTAL BIOLOGY & MEDICINE,WILLIAMS AND WILKINS,XX, vol. 101, August 1959 (1959-08-01), pages 617 - 621, XP000965627, ISSN: 0037-9727 *
RIMM E B ET AL: "FOLATE AND VITAMIN B6 FROM DIET AND SUPPLEMENTS IN RELATION TO RISK OF CORONARY HEART DISEASE AMONG WOMEN", JAMA THE JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION,CHICAGO,IL,US, vol. 279, no. 5, 4 February 1998 (1998-02-04), pages 359 - 364, XP000965325, ISSN: 0098-7484 *
VASUDEV, SINDHU C. ET AL: "Glutaraldehyde-treated bovine pericardium: changes in calcification due t vitamins and platelet inhibitors", ARTIF. ORGANS (1997), 21(9), 1007-1013, 1997, XP001004729 *
VIDRIO H: "INTERACTION WITH PYRIDOXAL AS A POSSIBLE MECHANISM OF HYDRALAZINE HYPOTENSION", JOURNAL OF CARDIOVASCULAR PHARMACOLOGY,NEW YORK, NY,US, vol. 15, no. 1, 1 January 1990 (1990-01-01), pages 150 - 156, XP000965625, ISSN: 0160-2446 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8067444B2 (en) 2003-06-20 2011-11-29 Nephrogenex, Inc. Pyridoxamine for the treatment of diabetic intermediaries and post-amadori inhibition

Also Published As

Publication number Publication date
US20040038945A1 (en) 2004-02-26
EP1210117A2 (en) 2002-06-05
EP1872797A3 (en) 2008-04-02
US7115625B2 (en) 2006-10-03
US20040033992A1 (en) 2004-02-19
EP1872797A2 (en) 2008-01-02
US7144892B2 (en) 2006-12-05
US7132430B2 (en) 2006-11-07
US20040033991A1 (en) 2004-02-19
CA2383252A1 (en) 2001-03-01
US20040033990A1 (en) 2004-02-19
US20040033989A1 (en) 2004-02-19
US6677356B1 (en) 2004-01-13
JP2003507418A (en) 2003-02-25
US7148233B2 (en) 2006-12-12
WO2001013900A2 (en) 2001-03-01
US7115626B2 (en) 2006-10-03
AU6814400A (en) 2001-03-19
US7125889B2 (en) 2006-10-24
AU783855B2 (en) 2005-12-15
US20040033993A1 (en) 2004-02-19

Similar Documents

Publication Publication Date Title
WO2001013900A3 (en) Compositions for the treatment of cardiovascular diseases containing pyridoxal compounds and cardiovascular compounds
ATE259643T1 (en) PYRIDOXINE DERIVATIVES IN THE TREATMENT OF CARDIOVASCULAR DISEASES
NO20075065L (en) Use of isoflavone compounds to treat heart disease
CA2356300A1 (en) 3-azabicyclo[3.1.0]hexane derivatives useful in therapy
HUT68391A (en) Heterocyclic compounds substituted with side chain containing thio and carbonyl-amino-groups, pharmaceutical preparations containing said compounds as dual action inhibitors and process for preparing them
EG23729A (en) N-alkanoylphenylalanine derivatives
MY129295A (en) N-alkanoylphenylalanine derivatives
TW245718B (en)
AP2000001929A0 (en) Substituted indolealkanoic acids.
MY119800A (en) Pyridine derivatives
MY126972A (en) 4-pyrimidinyl-n-acyl-l-phenylalanines
WO1999004752A3 (en) Methods for treating skin pigmentation
EP1077063A3 (en) Methods for treating skin pigmentation
CA2348735A1 (en) Heterocyclic potassium channel inhibitors
MXPA02005510A (en) Compounds, compositions, and methods for stimulating neuronal growth and elongation.
YU24402A (en) 2'-substituted 1,1'-biphenyl-2-carbonamides, method for the production thereof, use thereof as a medicamt and pharmaceutical preparations containing said compounds
HUT40331A (en) Process for preparing pharmaceutical compositions containing a combination of dihidro-pyridines and ace-inhibitors
WO2000021910A3 (en) 1,2-disubstituted cyclopropanes
EP0981352B8 (en) Use of aplidine for the treatment of cardiovascular diseases
CA2362343A1 (en) Method and composition for treating acne
WO2002100836A8 (en) Compounds, compositions and methods for modulating beta-amyloid production
ATE120190T1 (en) 5-FLUORINE-2,4,6-PYRIMIDINTHIAMINE DERIVATIVES TO PREVENT HAIR LOSS.
ZA979647B (en) Heterocyclic compounds, compositions and uses.
ZA979645B (en) Heterocyclic compounds, compositions and uses.
CA2254528A1 (en) Treatment of ischemia reperfusion injury and treatment of cellular dysfunction including arrhythmia and heart failure subsequent to myocardial infarction

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ CZ DE DE DK DK DM DZ EE EE ES FI FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ CZ DE DE DK DK DM DZ EE EE ES FI FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

WWE Wipo information: entry into national phase

Ref document number: 2383252

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 68144/00

Country of ref document: AU

Ref document number: 200068144

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2000956009

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2000956009

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWG Wipo information: grant in national office

Ref document number: 200068144

Country of ref document: AU

DPE2 Request for preliminary examination filed before expiration of 19th month from priority date (pct application filed from 20040101)